(Melanoma) Tafinlar and Mekinist Receive Manufacturing and Marketing Approval in Japan

In a press release issued on March 28, Novartis announced that the BRAF inhibitor Tafinlar (dabrafenib) and the MEK inhibitor Mekinist (trametinib) have received manufacturing and marketing approval in Japan for the treatment of BRAF-mutant unresectable malignant melanoma.

BRAF is an important signaling protein for cell proliferation. When BRAF V600 gene mutations occur, the related MEK protein becomes overactivated, generating stronger signals that drive cancer cell proliferation and metastasis.

In Japan, an estimated 20–30% of malignant melanoma patients carry BRAF V600 gene mutations. The basis for this approval was overseas Phase III clinical trials — MEK116513 (COMBI-v), MEK115306 (COMBI-d), and BRF113683 (BREAK-3) — as well as Japan-domestic Phase I/II trials MEK116885. The combination therapy demonstrated equivalent efficacy in both Japanese and Western populations.

Adverse events observed in Japan-specific Tafinlar monotherapy studies:

• Hair loss, elevated body temperature, joint pain: each approximately 50%

Adverse events observed with Tafinlar + Mekinist combination therapy:

• Elevated body temperature: 66.7%
• Elevated AST (GOT): 50%
• Peripheral edema: 50%

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Melanoma